University of Texas at Tyler Scholar Works at UT Tyler

MSN Capstone Projects

Nursing

Winter 12-6-2020

Home Blood Pressure Monitoring

Bethany N. Hughes University of Texas at Tyler, bhughes9@patriots.uttyler.edu

Follow this and additional works at: https://scholarworks.uttyler.edu/nursing_msn

Part of the Nursing Commons

Recommended Citation

Hughes, Bethany N., "Home Blood Pressure Monitoring" (2020). *MSN Capstone Projects*. Paper 72. http://hdl.handle.net/10950/2770

This MSN Capstone Project is brought to you for free and open access by the Nursing at Scholar Works at UT Tyler. It has been accepted for inclusion in MSN Capstone Projects by an authorized administrator of Scholar Works at UT Tyler. For more information, please contact tgullings@uttyler.edu.

Home Blood Pressure Monitoring

A Paper Submitted in Partial Fulfillment of the Requirements

For NURS 5382: Capstone

In the School of Nursing

by

Bethany Hughes

December 6, 2020

Contents

Acknowledgements

Executive Summary

Benchmark Project

- 1. Rationale
- 2. Literature Synthesis
- 3. Project Stakeholders
- 4. Implementation Plan
- 5. Timetable/Flowchart
- 6. Data Collection and Planned Evaluation
- 7. Cost/Benefit Discussion
- 8. Discussion of Results

Conclusions/Recommendations

References

Appendices

Acknowledgements

Through the completion of this course and my final Capstone benchmark project, I have reached an extraordinary milestone in my educational career. I did not make it this far without tremendous support along the way. First, I would like to thank God for planting the seed in my heart for carrying out his work through my nursing career. I would also like to thank my late grandmother, Arrye Craig, for instilling in me the foundation for my passion for nursing. To my family, friends, and colleagues, I would like to express my deepest gratitude for the love, encouragement, and support as I have pursued my educational goals. Without each of you, this would not be possible. I would like to thank Dr. Colleen Marzilli for your support, understanding, and encouragement throughout the semester. I cannot be more thankful for the time you have taken to ensure the success of your students during this difficult time of managing our graduate nursing courses, current jobs, and families through a pandemic. To each instructor and preceptor who have invested in my educational pursuits and obtainment of advanced practice skills, there is no "thank you" large enough for the time you have taken to mold and guide me through this journey. Because of each of you, I stand in this moment and look to the future with great optimism for my future and the utmost gratitude in my heart.

Executive Summary

Hypertension is prevalent worldwide and is responsible for nine million deaths annually. Despite its prevalence, a majority of patients go unmanaged or undiagnosed (Kitt et al., 2019). Health complications of hypertension can be life-altering and life-threatening; therefore, if changes are not made to improve community hypertension control rates, worsened population health and financial burden on health systems may persist. Would you believe that an effective tool exists and has been endorsed worldwide to combat hypertension, yet it is not used consistently in practice? Furthermore, can you imagine this specific tool is easy to operate, cheap, and recruits patient involvement in their care? This tool is home blood pressure monitoring (HBPM), and it has the potential to improve blood pressure control.

In caring for patients with hypertension and other cardiovascular diseases for over five years, it is astounding to realize how many patients that are treated for hypertension do not have a blood pressure monitor at home. This realization sparked interest in creating an evidence-based project that utilizes home blood pressure monitoring to improve blood pressure control. A project for change has been created based on the following PICOT question: In adult patients diagnosed with hypertension (P), how does home blood pressure monitoring (I) compared to no blood pressure monitoring (C) affect blood pressure (O) twelve weeks after diagnosis (T)?

This project outlines that patients will participate in HBPM each morning for a twelveweek (3 month) period. Patients will follow up at one-week, four-week, and twelve-week intervals either by telehealth visit or in clinic visit to ensure close monitoring and safety. To evaluate the outcomes of the intervention blood pressure readings will be calculated to determine a change in blood pressure readings and evaluate blood pressure control rates over twelve weeks.

4

Home Blood Pressure Monitoring

Rationale for the Project

Hypertension is a health condition that is widely known within health care and in the public. Despite public knowledge and effective treatment options that are readily available, hypertension control rates are suboptimal (Zalloum et al., 2015). Health complications of hypertension can be life-altering and life-threatening. Furthermore, hypertension-related morbidity and mortality place a significant financial burden on health systems and society (Mills et al., 2016). These factors make hypertension management an important topic in the realm of improving population health.

Each clinical diagnosis of hypertension is unique, which can be challenging for the provider to effectively manage the disease. Equally as challenging, providers can be misguided in diagnosing or treating hypertension based on the single blood pressure that is measured in the clinic setting. A variety of factors can cause changes in blood pressure measurements that are taken at the time of evaluation. This can result in unnecessary medical therapy or negative health outcomes.

HBPM goes beyond what is seen in the clinic setting and extends a greater understanding of the overall health of the patient by revealing day to day variances in the patient's blood pressure. This can make blood pressure management more efficient and individualized to achieve optimal blood pressure control. Incorporating home blood pressure monitoring into the usual care of patients with hypertension is a more reliable method that has the potential to improve community hypertension control rates, improve population health, and decrease financial burden on health systems.

Literature Synthesis

A literature search was conducted by using four databases: Academic Search Complete, CINAHL Complete, Health Source: Nursing/Academic Edition, and PubMed. The search was limited by applying the search terms "blood pressure AND hypertension AND home monitoring". Further limitations included peer reviewed articles, full text, and dated between April of 2014 and September of 2020. Related words and equivalent subjects were also applied to the search. Twelve articles of varied levels of evidence were identified that provided overwhelming evidence to support the use of HBPM in the management of hypertension.

The most substantive evidence to support this project illustrates that HBPM contributes to effective blood pressure control when compared to clinic blood pressure monitoring (Cairns et al., 2018; Chmiel et al., 2014; Pan et al., 2018; Qi et al., 2017). The studies showed a significant change in blood pressure between the intervention group (HBPM) and control group over different periods of time. Cairns et al. (2018) and Chmiel et al. (2014) conducted their study over six months; whereas, Pan et al. (2018) studied patients up to 12 months, and Qi et al. (2017) conducted their study over five years. The literature also supports that HBPM is a simple cost-effective intervention that improves blood pressure control and encourages patient involvement in care management (Chmiel et al., 2014; Qi et al., 2017; Zalloum et al., 2015). Since compliance and acceptance by patients can be a barrier to evidence-based interventions, choosing an intervention that recruits patient involvement is more likely to ensure successful implementation.

Sharman et al. (2016) established a quick method for interpreting HBPM that revealed having three or more of the last ten home systolic blood pressure readings greater than 135 mmHg was a predictor for uncontrolled hypertension. This study determined that this method of HBPM allowed providers to identify patients at risk for target organ disease and intervene sooner

6

to reduce morbidity and mortality related to hypertension (Sharman et al., 2016). A crosssectional correlation study by Zalloum et al. (2015) found that patients with hypertension who performed HBPM more frequently had significantly reduced blood pressure readings. Additionally, patients who performed HBPM had better compliance with their medications and reported healthier lifestyle habits such as decreased salt intake and exercise (Breaux-Shropshire, 2015; Zalloum et al., 2015). Three qualitative interview studies conducted by Bradbury et al. (2018) that found that patients viewed HBPM to be easy, beneficial, and empowering in the management of hypertension, and one mixed method study by Cairns et al. (2020) found that patients perceived a better sense of control over their health with HBPM.

Project Stakeholders

Identifying stakeholders is essential to gain support, reduce barriers, and understand critical perspectives when implementing and evidence-based intervention. For this HBPM project, the following stakeholders have been identified: patients with hypertension and their families, organization administration, the cardiology clinic manager, doctors, nurse practitioners, physician assistants, and nursing staff. Patients with hypertension and their families are considered the most important stakeholders for this project. Without gaining support from the patients, implementation will fail, because patients will be carrying out the intervention. Organizational administration and the cardiology clinic managers are essential stakeholders because approval for the project and project funds will have to be obtained for the intervention to be implemented. Additionally, doctors, nurse practitioners, physician assistants, and nursing staff providing care for patients with hypertension are important stakeholders because they can provide unique perspectives of suitable patients, safety considerations, and realistic expectations for the intervention and evaluation of project goals.

Planned Implementation

The successful implementation of an evidenced-based change project requires a thorough and well-prepared plan. The following plan is broken down by specific steps of the project that fit into each week through implementation. This should be followed step by step to ensure success with future implementation.

Week One

Step One: Approval

During week one, implementation planning will begin by gaining approval for the project from organizational leadership officials, the cardiology clinic manager, and participating providers. A formal meeting with a presentation of data that highlights the prevalence, morbidity, and mortality rates of hypertension in the community will be presented. Financial burden of hypertension on the institution, such as hypertension-related emergency room visits, hospitalizations, and long-term health complications, will be discussed. Approval for project funds must also be obtained.

Step Two: Team Recruitment

Also, during week one, the project team will be recruited. Four cardiology providers, two medical office assistants, two nurses, one information technologist, and one electronic health record specialist from the cardiology clinic will be needed. Realistic expectations will be provided on the role, responsibility, and length of the project to assist in recruiting team members that will commit to complete the project in its entirety.

Week Two

Step Three: Assignment of Team Roles

8

During week two, the project team will meet to discuss role responsibilities of each team member. The team will be provided with a presentation of the project plan, timeline, goals, and outcomes. During this meeting, collaboration by all members will allow for skill gaps to be discussed and filled. If skill gaps are identified that cannot be filled by current team members, recruitment of additional specialists is encouraged.

Step Four: Patient Recruitment

Also, during week two, patients will be recruited by providers in the cardiology clinic to participate in the project. For this piloted project, 30 adult patients with hypertension should be recruited to participate in HBPM. Patients must give informed consent to participate and agree to monitor their blood pressure daily for twelve weeks. At recruitment, background and contact information should be verified to assist with follow up. It should also be determined whether patients have their own blood pressure monitor or if one will need to be provided.

Week Three

Step Four: Patient Recruitment (Continued)

Week three will allow for an additional week of recruitment so that the project team is able to ensure the appropriate number of participants for the study. The recruitment process for week three will be the same as described for the previous week.

Week Four

Step Five: Patient Education

During week four, patients will be scheduled to attend educational sessions where patients are taught how to properly use their blood pressure monitor for the implementation phase of the project. Blood pressure monitors will be distributed for patients who do not have a home monitor. For patients wishing to use their own home monitor, devices must be confirmed as a validated device intended to use on the upper arm. Blood pressure cuffs will be approved for proper fit for each individual. Standardized blood pressure logs will be provided at this visit to each participant. An example of a similar blood pressure log is located in Appendix C. Baseline blood pressures will be established the same day as the educational sessions with the same monitor that the patient will be using at home. Patients will be provided with instructions for HBPM which include the following information:

- Perform HBPM in the morning before taking medications
- Use the same arm every day to monitor blood pressure readings
- Take the blood pressure reading after five minutes of being seated and with legs uncrossed
- Take two readings at least two minutes apart
- The second reading should be recorded

Week Five to Seventeen

Step Six: Implementation

Implementation of HBPM begins the Monday after educational sessions are completed. Patients will monitor their blood pressures daily for twelve weeks. Clinic staff, including medical office assistants, nurses, and providers should be prepared to answer or return calls promptly to assist patients through the first week of monitoring if questions are to arise. On the day of project implementation, clinic nurses will schedule participants follow up appointments and determine their preference for follow up, in clinic or via telehealth.

Step Seven: Follow Up

Follow up appointments will be scheduled for patients at one week, four weeks, and twelve weeks after implementation. Blood pressure logs will be reviewed, and data will be transcribed at each follow up appointment, either by direct transcription during in-clinic follow up appointments or transcribed from the patient portal for telehealth follow up appointments. Each follow up appointment should address patient perceptions, concerns, or needs. At the twelve-week follow up appointment, final blood pressure readings should be obtained and reviewed for completion.

Timetable/Flowchart

On August 24, 2020, a project proposal meeting will be held with organizational administration, the cardiology clinic manager, and other organization officials to gain approval for the project. Recruitment of project team members will occur during August 25 through August 28. Team roles will be assigned and a formal education session for team members will be held on August 31. Patient recruitment by providers will occur during a two-week period between September 1 and September 11. Educational sessions with patients will be held in the morning for about an hour and a half from September 14 to September 18, and baseline blood pressures will be established during these sessions. Implementation of HBPM will begin on September 21 and continue through the last follow up appointment held on December 14. Follow up appointments will be held on September 28, October 19, and December 14. Evaluation and interpretation of the HBPM data will be conducted between December 14 and December 18. A meeting to debrief with the project team will be held on December 18. A presentation will be created by volunteers from the project team will be allowed during the week of December 21 through December 27. On December 28, 2020 outcomes of the project will be disseminated to all stakeholders through a formal presentation.

The flow of events depicts the suggested timeline of this benchmark study. Dates are provided to give future direction for the project to be replicated with a different population.

HBPM and the evaluation of outcomes for this project has a linear flow due to the simplicity of the intervention and the outcomes to be evaluated; therefore, there is little overlapping or simultaneous processes being evaluated. This is reflective in the flowchart and the dates provided. The flowchart for the project is located in Appendix B.

Data Collection and Planned Evaluation

Initially, education sessions will be scheduled for all 30 patients the week prior to implementation. Baseline blood pressures will be established on the day of education sessions, and this blood pressure data will be used to compare future readings throughout follow up. Patients will be provided with a standardized blood pressure log to document their readings. The implementation phase begins with patients monitoring their blood pressure at home, and this will be continued for a total of twelve weeks. Patients will be required to follow up after implementation at specific intervals: one week, four weeks, and twelve weeks. Blood pressure data will be obtained at each follow up appointment either by direct transcription of blood pressure logs for those who choose to attend follow up by traditional clinic visits or by transcribing readings that are uploaded into the online patient portal for those choosing telehealth follow up appointments.

At the designated follow up appointment one week after implementing HBPM, nursing staff will be responsible for transcribing each patient's blood pressure values of day one through day seven into a database. This process will be the same for the four-week and twelve-week follow up appointment in which nursing staff will transcribe blood pressure data for each patient of days eight through 28 and days 29 through the completion day of the project, respectively.

12

After the implementation phase is complete and all data is obtained, blood pressure data will be verified for completeness and the data will be evaluated to determine if outcome goals are met.

The two primary goals for this project that gauge the project for success include:

- 1. Have 25 of the 30 participants complete the project entirely (83.3%).
- 2. Have 15 patients achieve blood pressure control by the end of the three-month period (50%).

After a review of the data, it will be determined how many patients completed the project entirely by manually counting how many participants had at least one blood pressure reading documented in the logbook for every day throughout the intervention period. Blood pressure readings for each patient will be calculated to determine each patient's mean systolic and diastolic blood pressure at one week, four weeks, and twelve weeks after implementation using the data within the follow up period described previously. Data will also be calculated to determine the percentage of patients that achieved or maintained blood pressure control after the three-month period of applying HBPM. Blood pressure control will be determined by greater than fifty percent of blood pressure readings less than 140/90. This will be conducted by identifying the number of patients with an average blood pressure for the 12-week follow up period less than 140/90 and dividing it by the number of patients that participated in the study. This will reveal the percentage of patients achieving blood pressure control. If at least 50 percent of patients achieve blood pressure control and at least 25 patients complete the study entirely, then the intervention will be successful.

Cost/Benefit Discussion

Cost consideration is an important component of an evidence-based intervention project. Calculating the cost to plan, implement, and evaluate the project, as well as determining fees for services provided by the project team, is essential to gain support for the project by administration and determine if the investment is worth the expenditure for the organization. For this HBPM project, costs are minimal due to the simplicity of the intervention; therefore, a majority of the costs will be spent on staffing educational sessions, follow-up visits, and evaluation processes.

The following hourly rates will be used to estimate staff costs for training and services provided for the project: providers (\$150/hour), nurses (\$25/hour), medical office assistant (\$15/hour), information technologist (IT) (\$20/hour), and electronic health record (EHR) specialist (\$20/hour). Four physicians, two nurses, two medical office assistants, one IT personnel, and one EHR specialist will be needed. For the planned two-hour staff training education session, costs include: \$1,200 for providers, \$100 for nurses, \$60 for medical office assistants, \$40 for the IT, and \$40 for the EHR specialist for an approximate total of \$1,440. To provide nursing staff for the planned patient education sessions for five days that will last one and a half hours each day, it will cost \$375. Provider costs for the scheduled follow up appointments for each patient (15-minute sessions for three follow up visits) will cost approximately \$3,375. Additional funding to have nursing staff assistance to transcribe blood pressure log data into the database for all three follow up appointments will cost approximately \$960. Standardized blood pressure logs will need to be printed and provided for each of the 30 patients, and this is estimated to cost approximately \$100. A blood pressure fund of \$1,000 will allow for blood pressure monitors to be provided for all 30 patients. Some patients may have

their own monitor that they wish to use; therefore, the entire fund may not be used. For this project, the total funding needed to support this HBPM project is approximately \$7,250.

According to a study by Kirkland et al. (2020), annual healthcare expenditure costs for one patient with hypertension is approximately \$1,920 compared to patients without hypertension. Since the goal for this project is to have 50 percent of patients achieve blood pressure control with the use of HBPM, if 15 patients do achieve blood pressure control then HBPM has the potential to save the organization \$28,800 in just one year. If the total cost of the project is approximately \$7,250 and the potential savings for organization is approximately \$28,800, the net savings for the institution is \$21,550 annually for only 15 patients achieving and maintaining blood pressure control.

Discussion of Results

Although this project is presented in the form of a benchmark project, support for future implementation has been expressed by multiple providers and staff within the current organization. This important to ensure successful implementation in the future. At the end of the implementation period, patients' blood pressures will be evaluated for change over time. For this project to be deemed successful, at least 25 patients must complete the project entirely and at least 15 patients must obtain blood pressure control. These specific goals have been set to improve the health of the targeted project population and offload some financial burden on the institution related to hypertension. Goals for this project are set with very realistic measures for a piloted HBPM project; therefore, it is suspected that these goals will be obtained when the project is implemented. It is also suspected that institution and participant costs, as well as adverse outcomes related to the project, will be minimal.

Conclusions/Recommendations

In creating a benchmark HBPM project that was not actually conducted, it is important to make plans for implementation and consider future directions of the project. The next step is to move toward actual implementation. As preparations are made to implement this benchmark project, it is important to partner with an organization that supports evidence-based practice and has a quality improvement framework to ensure sustainment of the HBPM intervention (Kumar et al., 2015). Considering new technological innovations to assist in delivery and evaluation of outcomes is another important component to consider with future implementation. For example, using a blood pressure monitor that can directly upload patient data to the electronic health record patient portal could reduce errors in transcribing data and result in more accurate evaluation of data. Additionally, expansion of the HBPM intervention to a larger population of patients is ideal to provide a larger impact on population health and relieve hypertension-related financial burdens on the healthcare system.

If for some reason, the HBPM intervention were not approved by organizational leadership, formal education with providers on the importance of HBPM or proposing the establishment of a hypertension clinic could improve patient outcomes could encourage the use of HBPM in the management of hypertension without having a formal project. As a future nurse practitioner, it is recommended that HBPM be used in the management of all patients with hypertension that are physically and mentally able to perform the task based on the overwhelming evidence that already exists. It is recommended that the facility develop a protocol for HBPM patient education to be presented annually for all patients with hypertension. Colleagues, patients, and leadership are encouraged to communicate the importance of hypertension management throughout the community to encourage patients and future patients to seek routine health exams and hypertension screening to reduce hypertension-related morbidity and mortality. These strategies encourage a healthier population for generations to come.

References

- Aekplakorn, W., Suriyawongpaisal, P., Tansirisithikul, R., Sakulpipat, T., & Charoensuk, P. (2016). Effectiveness of self-monitoring blood pressure in primary care: A randomized controlled trial. *Journal of Primary Care & Community Health*, 7(2), 58–64. https://doiorg.ezproxy.uttyler.edu/10.1177/2150131915614069
- Bradbury, K., Morton, K., Band, R., van Woezik, A., Grist, R., McManus, R. J., Little, P., & Yardley, L. (2018). Using the Person-Based Approach to optimise a digital intervention for the management of hypertension. *PLoS ONE*, *13*(5), 1-18. https://doi.org/10.1371/journal.pone.0196868
- Breaux-Shropshire, T. L., Judd, E., Vucovich, L. A., Shropshire, T. S., & Singh S. (2015). Does home blood pressure monitoring improve patient outcomes? A systematic review comparing home and ambulatory blood pressure monitoring on blood pressure control and patient outcomes. *Integrated Blood Pressure Control, 8*, 43-49. https://doi.org/10.2147/IBPC.S49205
- Cairns, A. E., Tucker, K. L., Crawford, C., McManus, R. J., & Powell, J. (2020). Implementing self-management: a mixed methods study of women's experiences of a postpartum hypertension intervention (SNAP-HT). *Trials, 21*(1), 508. https://doi.org/10.1186/s13063-020-04394-z
- Cairns, A. E., Tucker, K. L., Leeson, P., Mackillop, L. H., Santos, M., Velardo, C., Salvi, D., Mort, S., Mollison, J., Tarassenko, L., & McManus, R. J. (2018). Self-management of postnatal hypertension: The SNAP-HT trial. *Hypertension*, 72(2), 425–432. https://doi.org/10.1161/HYPERTENSIONAHA.118.10911

- Chmiel, C., Senn, O., Rosemann, T., Del Prete, V., & Steurer-Stey, C. (2014). CoCo trial: Colorcoded blood pressure control, a randomized controlled study. *Patient Preference & Adherence, 8*, 1383–1392. https://doi.org/10.2147/PPA.S68213
- de Heus, R. A., Tumelaire, M. V., Olde Rikkert, M. G., & Claassen, J. A. (2019). Diagnostic accuracy of office blood pressure compared to home blood pressure in patients with mild cognitive impairment and dementia. *European Journal of Cardiovascular Nursing*, 18(7), 637-642. https://doi.org/10.1177/1474515119855822
- Kirkland, E. B., Heincelman, M., Bishu, K. G., Schumann, S. O., Schreiner, A., Axon, R. N., Mauldin, P. D., & Moran, W. P. (2018). Trends in healthcare expenditures among US adults with hypertension: National estimates, 2003-2014. *Journal of the American Heart Association*, 7(11). https://doi.org/10.1161/JAHA.118.008731
- Kitt, J., Fox, R., Tucker, K. L., & McManus, R. J. (2019). New approaches in hypertension management: A review of current and developing technologies and their potential impact on hypertension care. *Current Hypertension Reports*, 21(6), 44. doi:10.1007/s11906-019-0949-4
- Kumar, S., Kumar, N., Deshmukh, V., & Adhish, V. S. (2015). Change management skills. *Indian Journal of Community Medicine : Official Publication of Indian Association of Preventive & Social Medicine*, 40(2), 85–89. https://doi.org/10.4103/0970-0218.153869
- Mills, K. T., Bundy, J. D., Kelly, T. N., Reed, J. E., Kearney, P. M., Reynolds, K., Chen, J., & He, J. (2016). Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. *Circulation*, 134(6), 441–450. https://doi.org/10.1161/CIRCULATIONAHA.115.018912

- Pan, F., Wu, H., Liu, C., Zhang, X., Peng, W., Wei, X., & Gao, W. (2018). Effects of home telemonitoring on the control of high blood pressure: A randomised control trial in the Fangzhuang Community Health Center, Beijing. *Australian Journal of Primary Health, 24*(5), 398–403. https://doi.org/10.1071/PY17187
- Qi, L., Qiu, Y., & Zhang, W. (2017). Home blood pressure monitoring is a useful measurement for patients with hypertension: A long-term follow-up study. *Biomedical Research*, 28(7), 2898-2902.
- Sharman, J. E., Blizzard, L., Kosmala, W., & Nelson, M. R. (2016). Pragmatic method using blood pressure diaries to assess blood pressure control. *Annals of Family Medicine*, 14(1), 63-69. https://doi.org/10.1370/afm.1883
- Spirk, D., Noll, S., Burnier, M., Rimoldi, S., Noll, G., & Sudano, I. (2018). Effect of home blood pressure monitoring on patient's awareness and goal attainment under antihypertensive therapy: The factors influencing results in anti-hypertensive treatment (FIRST) study. *Kidney & Blood Pressure Research, 43*(3), 979–986. https://doi-org.ezproxy.uttyler.edu/10.1159/000490687
- Zalloum, N. A., Farha, R. A., Ruqa'a, A. M., Khdair, A. A., & Basheti, I. A. (2015). Blood pressure home monitoring in hypertensive patients attending a tertiary health facility in Amman, Jordan: Effect on disease control and adherence rate. *Tropical Journal of Pharmaceutical Research*, 14(3), 533-538. doi:10.4314/tjpr.v14i.

Appendix A

PICOT Question: In adult patients diagnosed with hypertension (P), how does home blood pressure monitoring (I) compared with no blood pressure monitoring (C) affect blood pressure (O) twelve weeks after diagnosis (T)?

PICOT Question Type (Circle): Intervention Etiology Diagnosis or Diagnostic Test Prognosis/Prediction Meaning

Citation: (i.e., author(s), date of publication, & title)	Conceptual Framework	Design/ Method	Sample/ Setting	Major Variables Studied and Their Definitions	Measurement of Major Variables	Data Analysis	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
Author, Year, Title	Theoretical basis for study Qualitative Tradition		Number, Characteristics, Attrition rate & why?	Independent variables (e.g., IV1 = IV2 =) Dependent variables (e.g., DV =)	What scales were used to measure the outcome variables (e.g., name of scale, author, reliability info [e.g., Cronbach alphas])	What stats were used to answer the clinical question (i.e., all stats do not need to be put into the table)	Statistical findings or qualitative findings (i.e., for every statistical test you have in the data analysis column, you should have a finding)	 Strengths and limitations of the study Risk or harm if study intervention or findings implemented Feasibility of use in your practice Remember: level of evidence (See Melnyk & Finout-Overholt, pp. 32-33) + quality of evidence = strength of evidence & confidence to act Use the USPSTF grading schema http://www.ahrq.gov/clinic/3rduspstf/ratings. htm

Qi, Qiu, &	None	Double-blind	n=1183	IV: HBPM vs	Validated and	Mean (SD)	SBP \downarrow for SOG: 4.3 (± 3.2)	Strengths: HBPM endorsed by international
Zhang, 2017,	stated	RCT	CG: n= 596	CBPM	approved	× /	SBP \downarrow for CG: 3.9 (\pm 3.1)	guidelines, ↑ patient engagement, cost-effective,
Home blood			SOG: n= 587		automated BP		DBP \downarrow for SOG: 3.5 (±	simple intervention, extended follow-up period
pressure				DV1: BP	device for SOG		2.5)	
monitoring is			Recruited at	control			DBP \downarrow for CG: 3.0 (± 2.5)	Limitations: patient adherence to intervention,
a useful			community	DV2:	BP recorded			attrition
measurement			hypertension	adherence	within 1 hour of	Percentages	Improved at goal BP:	
for patients			management		awakening and	(%)	SOG: 85.37%	Risk/harm: lack of BP control and development
with			center		after seated for 5		CG: 79.96%	of complications
hypertension:					minutes			
A long-term			Characteristics:					Feasibility: feasible for use in current and future
follow-up			-Sex: M (SOG:			m . 11.1.		practice
study.			290, CG: 499);			I wo-tailed t-	SBP and DBP for SOG	
			F (SOG: 243,			test	and CG: $p < 0.05$	Level of Evidence: RC1-Level 2
			A get (SOC)					USPETE: Crade: D. Level of containtry
			-Age. (300.					Moderate
			05.5 ± 11.4 , CG: 64.5 +					Moderate
			10.2)					
			-DM: (SOG:					
			23% CG:					
			32%)					
			-Smoking:					
			(SOG: 32%,					
			CG: 34%)					
			-BMI: (SOG:					
			28.1 ± 3.4 , CG:					
			$27.5 \pm 3.7)$					
			-CHOL:					
			(SOG: $6.1 \pm$					
			$0.7, CG: 5.9 \pm$					
			0.6)					
			· · · · ·					
			Attrition:					
			relocation					
			(SOG: 24, CG:					
			follow up					
			(SOG: 22 CG:					
			76) death					
			(SOG: 10, CG)					
			7)					

Sharman, Blizzard	None stated	RCT	n = 286	IV: HBPM vs CBP	CBP: automated	Mean (SD)	Last 10 readings with < 3 elevations:	Strengths: HBPM widely used, ↑ patient adherence to therapy standardized method for
Kosmala &	Stated		Recruited	СЫ	device (HEM-907:		ABP daytime SBP:	HBPM
Nelson,			through general	DV: BP	OMRON Europe		$132.7 (\pm 11.1)$	
2016,			practice clinics	control, AS,	BV) after seated		• HBP SBP: 120.4 (±	Limitations: \downarrow sample size, patient error in
Pragmatic			and community	LVRWT,	for 5 minutes		9.8)	recording BP, not applicable to patients with BP
method using			advertisement	LVMI, LVEF,			Last 10 readings with ≥ 3	> 180/100
blood			in Australia	LAA, EVFP	7d HBP: BP		elevations:	
pressure					device (UA767,		 ABP daytime SBP: 	Risk/harm: lack of BP control and development
diaries to			Characteristics:		A&D Mercury),		143.4 (± 11.2)	of target organ disease
assess blood			-Age: 64 (8)		duplicate		• HBP SBP: 147.4(±	
pressure			-Sex (F): 53%		measurements, I		10.5)	Feasibility: feasible for use in current and future
control.			-BMII: 29.4		min apart, only	Doroonto goo		practice
			(4.0) CRD-[SRD-		second level	(%)	Controlled HBP (<135mm	Level of Evidence: PCT Level 2
			134 (14) DRP		3x/day after	(70)	Hg):34%	Level of Evidence. Re 1- Level 2
			78 (10)]		seated for 5		Controlled daytime ABP	USPSTF: Grade: B: Level of certainty:
			-24h ABP:		minutes, apply		(<135hini 11g). 4476	Moderate
			[SBP: 133 (12),		usual guidelines			
			DBP: 77 (8)]		for BP	Sensitivity	(> 3 cut point):	
			-7d HBP:				Mean 24h ABP SBP \geq	
			[SBP: 128 (13),		24h ABP: BP		130: 62.1%	
			DBP: 74 (8)]		device (TM-2430,		Mean 24h ABP daytime	
					A&D Mercury),		SBP ≥ 130: 64.6%	
			Measurement		measurements	G .C .		
			of IOD: $A = 0.4 (2.1)$		every 30 min 6A-	Specificity:	$(\geq 3 \text{ cut point})$:	
			-AS: 9.4 (2.1) I VPWT: 0.47		10P, every 60 mm		Mean 24h ABP SBP \geq	
			(0.20)		101-0/4		130: 80.2%	
			-LVMI: 31 3		AS: tomometric		Mean 24h ABP daytime	
			(5.5)		carotid-to-femoral		$SBP \ge 130$: //.2%	
			-LVEF: 62 (5)		pulse wave			
			-LAA: 20.4		velocity			
			(4.2)		(SphygmoCor 8.0,			
			-LVFP: 11.6		AtCor Medical)			
			(3.6)					
					LVMI & LVEF:			
			Attrition:		real-time 3D			
			Not discussed		echocardiography			
					LVFP: pulsed-			
					wave Doppler.			

Bradbury.	None	Oualitative	n = 30	IV: HBPM vs	HOME BP digital	Oualitative	Study 1 & 2:	Strengths: direct quotations from patient
Morton.	stated	interview		CBP	intervention.	data	HOME BP benefit:	perspective. \uparrow patient engagement. easy
Band, van		study	Recruited from		Band, Morton,		-Control over health	intervention
Woezik.			Primary Care	DV: patients'	Stuart, Raftery,		-Pleased to learn correct	
Grist.			practices in	perceptions of	Bradbury		method of HBPM	Limitations: sample size, information
McManus			South England	HBPM	McManus (2016)		-Eliminates wait for	regarding pt experience with medication
Yardley.			8				physical appointment	changes, participants in study 3, variation in
2018, Using			Characteristics:		Interview		-More accurate readings	ethnic representation, requires computer literacy
the Person-			-Age (median):		questions		than CBP	
Based			S1 (69)		1		HOME BP concern:	Risk/harm: lack of BP control and development
Approach to			S2 (69)				- quality of service for	of complications
optimize a			S3 (65)				med changes	*
digital			-Sex (F):				-impersonal	Feasibility: feasible for use in current and future
intervention			S1 (6)				F	practice
for the			S2 (7)				Study 3:	
management			S3 (3)				HOME BP concern:	Level of Evidence: Qualitative Study- Level 6
of			-Yr since				-No consideration for	- ·
hypertension.			diagnosis				factors that affect BP	USPSTF: Grade B; Level of certainty: Low
			(median):				-Security risk for	
			S1 (8)				sending online info	
			S2 (20)				-Distrust in online	
			S3 (10)				provider	
			-Ethnicity				*	
			(WB):				Patients in all studies:	
			S1 (11)				general belief that HBPM	
			S2 (10)				is empowering, easy,	
			S3 (7)				beneficial.	
			-Employment					
			(retired):			Iterative	-BP instructions made	
			S1 (9)			analysis	clearer, repeated	
			S2 (7)				-Explained BP varies	
			S3 (5)				naturally	
							-Changed BP procedure to	
			Attrition:				1 wk of practice	
			Not discussed				-Added diet sodium	
							information	
							-Added BP cuff	
							information	
							-Reinforced that provider	
							would adjust meds, not	
							website	
							-Changed information to	
							state that HOME BP Is	
							secure	

Zalloum	None	Cross-	n = 205	IV · HBPM vs	Questionnaire	Mean (SD)	-HBPM: 15.5 (+ 7.83)	Strengths: popular method intervention
Farha.	stated	sectional	11 200	CBP	Questionnane	(DD)	times/month	accepted by patients and providers. observer
Ruga'a		correlation	Recruited from		Stringent protocol		-Low BP: $4.1 (\pm 1.04)$	bias white coat effect, inexpensive
Khdair. &		study	cardiovascular	DV: adherence	in data collection		times/month	intervention
Basheti.			clinics at	to BP meds.	to reduce bias by		-High BP: 3.1 (± 1.2)	
2015. Blood			Jordan	BP control	researchers		times/month	Limitations: role of pharmacist was not
pressure			University					investigated, socioeconomic factors not
home			Hospital			Percentages	-Don't forget BP meds:	discussed, methodology not sufficient to draw
monitoring in			1			(%)	69.3%	clear conclusions
hypertensive			Characteristics:			· · /	-Don't stop BP meds for	
patients			-Age: 50-69				any reason: 89.4%	Risk/harm: lack of BP control and development
attending a			years: 59%				-Stopped BP meds for side	of complications
tertiary			-Sex(F): 52.7%				effects: 25.7%	-
health			-Employed:				-↑ salt intake for low BP:	Feasibility: Feasible for use in current and future
facility in			30%				52.8%	practice
Amman,			-Retired: 34%				-↓ salt intake for high BP:	
Jordan:			-Bachelor's				75.6%	Level of Evidence: Descriptive Study- Level 6
Effect on			degree: 32.2%				-Doctor or ER visit for BP:	
disease			-Diagnosis 10-				54.8%	USPSTF: Grade: B; Level of Certainty:
control and			20 yrs: 37.1%					Moderate
adherence						Spearman's	-Older age and use of air	
rate.			Attrition: not			correlation	meter/mercury meter:	
			discussed			(r)	(r = 0.239, p = 0.001)	
							-↑ frequency of BP reading	
							and stabilized BP:	
							(r = -0.232, p = 0.002)	
						• • •	4 1.1 1.1	
						Logistic	-Association with	
						Regression	adherence to medication:	
						Analysis	• Education level	
							(higher): $(p = 0.044)$	
							• BP readings (low): $(p = 0.002)$	
							0.002)	
		1	1	1				

Chmiel, Senn, Rosemann, Del Prete, & Steurer-Stey, 2014, CoCo trial: Color- coded blood pressure control, a randomized controlled study.	None stated	RCT	n = 121 Recruited by GPs in Zurich and St. Gallen, Switzerland. Characteristics: -Age: [IG: 61.5 (±13.1), CG: 62 (±12.6)] -Sex (M): [IG: 53.9%,	IV1: CoCo HBPM vs Standard HBPM DV: patients' perceptions of HBPM	Automated electronic oscillometric BP device (MioStar Cardioplus 500) was used for CBP and HBPM- validated for accuracy by EUM norm (EN1060). Cuff sizes were chosen by GPs to fit each patient	Mean (SD) Percentages	-SBP after 6 months: [IG: 141.4 (±13.0), CG: 146.4 (±17.9)] -DBP after 6 months: [IG: 83.8(±9.8), CG: 84.2 (±11.7) -BP control: (IG: 43.1%, CG: 25%) -HBPM adherence: (IG: 98.6%, CG: 96.2%) -BP med changed after 6 months: (IG: 59.7%, CG: 68.1%)	Strengths: randomized controlled study, ↑ patient decision-making, ↑ patient health strategies, BP improvement without medication changes, simple intervention Limitations: ↓ sample size, lack of blinding, ↓ patient-GP interaction, no evening or daytime measurements Risk/harm: lack of BP control and development of complications Feasibility: Feasible for use in current and future practice
			CG: 44.6%] -BMI: [IG: 28.2 (± 4.3) , CG: 28.8 (± 5.4)] -Smokers: [IG: 21.5%, CG: 23.2%] -# of BP meds: [IG: 1.3 (± 0.9) , CG: 1.6 (± 1.0)] -SBP: [IG: 157 (± 15.3) , CG: 159.5 (± 13.2)] -DBP: [IG: 91.8 (± 7.6) , CG: 92.8 (± 9.6)] Attrition: -Not met inclusion criteria: (IG: 3, CG: 8) -Not met exclusion criteria: (IG: 2, CG: 3)		Patient BP instructions: • every AM before meds • seated • after resting for 5 minutes • left upper arm with arm resting on table	Multi-level regression analysis	-Reduced SBP for IG: (regression coefficient - 4.26, 95% CI -7.85, -0.68; p = 0.020) -Reduced DBP for IG: (regression coefficient - 1.03, 95% CI -4.22, 2.15; p = 0.53	Level of Evidence: RCT- Level 2 USPSTF: Grade: B; Level of certainty: Moderate

Cairns	None	RCT	n = 82	IV1: HBPM	Validated BP	Mean (SD)	-SBP after 6 weeks: [IG:	Strengths: 1 patient decision-making simple
Tucker.	stated	ner	1 02	vs CBP	device was used	(SD)	121.6 (8.7), CG: 126.6	intervention, adequate follow-up visits and
Leeson.	stated		Recruited from	is obt	for HBPM		(+11.0)]	length of follow up, limited detection bias by
Mackillop.			five National	DV:	(Microlife		-DBP after 6 weeks: [IG: 80 5	using a validated BP monitor, convenient
Santos.			Health Service	Feasibility.	WatchBP Home)		(+6.6) CG: 86.0 $(+9.7)$]	follow-up visits at home.
Velardo.			hospital sites in	BP control			-SBP after 6 months: $[IG:$	up
Salvi, Mort.			England		The same BP		125.8 (+12.0) CG: 126.8	Limitations: sample size, lack of blinding,
Mollison.					device was used		(± 14.0)]	diversity in ethnicity and socioeconomic
Tarassenko, &			Characteristics:		for follow-up		(± 14.0)] SBP after 6 months: [IG:	status of participants, trial was not powered to
McManus,			-Age:		visits.		(+8.2) CG: 85.5 (+0.0)]	detect a difference in secondary outcomes
2018, Self-			[IG: 31.7 (±5.3),				$(\pm 0.2), CG. (0.5.5) (\pm 9.9)$	
management			CG: 31.7 (±5.3)]		Cuff sizes were	Percentages	-Retention rate at 6 weeks:	Risk/harm: lack of BP control and
of postnatal			-Mean BMI:		determined by arm		(IG: 89% CG: 91%)	development of complications
hypertension:			[IG: 29.0 (+7.5).		circumference		-Retention rate at 6 months:	
The SNAP-			CG: 28.0 (+8.3)]		measurement.		(IG: 91% CG: 94%)	Feasibility: Feasible for use in current and
HT trial.			-Parity:				-F/U visits attended by	future practice
			0: (IG: 32 CG: 31)				population that finished F/U	
			≥1: (IG: 13 CG:				(98%)	Level of Evidence: RCT- Level 2
			15)				Mean of readings 2 & 3	
			-Median				-BP in target range at F/U (6	USPSTF: Grade: B; Level of certainty:
			Gestation at				weeks): (IG: 93%, CG: 62%)	Moderate
			Diagnosis:				-BP in target range at F/U (6	
			[IG: 35.9), CG:				months): (IG: 80%, CG: 62%)	
			34.7]				Mean of readings 2-6	
							-BP in target range at F/U (6	
			Attrition:				weeks): (IG: 88%, CG: 60%)	
			-Withdrew during				-BP in target range at F/U (6	
			follow up (IG: 5,				months): (IG: 75%, CG: 67%)	
			CG: 4)					
						A 1° / 1	-SBP after 6 weeks: -5.2	
						Adjusted	(-9.3 to -1.2)	
						Difference	-DBP after 6 weeks: -5.8	
						(05% CI)	(-9.1 to -2.5)	
						(35/0 CI)	-SBP after 6 months: -1.0	
							(-6.3 to 4.4)	
							-SBP after 6 months: -4.5	
							(-8.1 to -0.8)	

de Heus, Tumelaire, Olde Rikkert, & Claassen,	None stated	Cross- sectional study	n = 213 Recruited from a memory clinic at a	IV1: HBPM vs CBP DV:	Validated, memory equipped, automatic BP	Mean (SD)	Mean home SBP compared to CBP: -16.8 Mean home DBP compared to CBP: -5.0	Strengths: validated BP device, ↑ patient involvement, simple intervention, large age diversity, evaluated patients with varied cognitive function.
2019, Diagnostic accuracy of office blood pressure compared to home blood pressure in patients with mild cognitive impairment and dementia.			university teaching hospital between 2014 and 2017. Characteristics: -Age: DEM group: 77.3 (7.4) MCI group: 74.4 (8.0) CN group: 67.5 (8.8) -Sex (F): DEM group: 45.1 (37) MCI group: 43.1 (28) CN group: 36.4 (24) - # of Drugs: DEM group: 4 (2–7) MCI group: 5 (1- 8) -Use of BP meds: DEM group: 61.0 (50) MCI group: 56.9 (37) CN group: 56.9 (37) - History of CV disease: DEM group: 46.3 (38) MCI group: 46.3 (38) MCI group: 56.1 (37) Attrition: -Did not meet the minimum number of twelve BP readings: 25 -No CBP level for comparison: 23	Misdiagnosis of HTN	device was used for HBPM (Microlife WatchBP Home) Demonstration and written instruction for HBPM were provided. Duplicate morning (6A- 10A) and evening (5P-9P) measurements for 7 days. BP readings taken while sitting for 5 minutes with arm supported by table.	Percentages Adjusted Odds Ratio	Disagreement in hypertension diagnosis between HBPM and <u>CBP</u> : Total sample: 31% DEM group: 35.4% MCI group: 38.5% CN group: 18.2% Disagreement in hypertension diagnosis: MCI group: 3.7 DEM group: 3.4 WCH: MCI group: 5.1 DEM group: 2.9	Limitations: possible bias due to variations in cognition, cannot ensure adherence to BP instructions, lacks long-term follow up. Risk/harm: lack of BP control and development of complications Feasibility: Feasible for use in current and future practice Level of Evidence: Descriptive Study- Level 5 USPSTF: Grade: B; Level of certainty: Moderate
				1	1	1		

Breaux-	None	Systematic	n = 19	IV1:	Jaded scale was	Qualitative	HBPM is as good or better	Strengths: comparison of multiple studies
Shronshire	stated	review		HBPM vs	used to assess	synthesis	than ABP monitoring for	with similar findings intervention
Judd	Stated	101101	Literature search	Ambulatory	research	5511010515	prediction of mortality for	encourages natient involvement
Vucovich			performed using these	RD	methodology and		p_{1}	intervention ancouraged medication
Shronghiro &			databagagy DubMad	DI	soiontific morit of		patients ≥ 60 .	adherence and adaption of healthy lifestyle
Sinopsinie, &			CDIALL (EDSCO)	DV. DD	DCT ₂ (assisted 1		Using UDDM to to meet	habits
Singn, 2015,			CINARL (EBSCO),	DV: BP	RC1s (assigned		Using HBPM to target	naous.
Does nome			Scopus, & Cochrane	control,	numeric score 1 to		antihypertensive treatment	T 1 1 1 1
blood pressure			Central (Wiley) using a	patient	5).		resulted in better BP	Limitations: small sample size,
monitoring			variety of search terms	outcomes			control for patients	malalignment of studies and systematic
improve			modified for each		Newcastle-Ottawa		receiving hemodialysis.	reviewers' interpretation of BP control,
patient			database. Two reviewers		scale was used to			variability of length of monitoring and
outcomes? A			independently reviewed		assess		Using HBPM to titrate BP	frequency of measurement,
systematic			each article.		observational		medication produces same	
review					studies.		level of control as ABP.	Risk/harm: lack of BP control and
comparing			Characteristics:					development of complications
home and			-Study type:				CBPM has lower	
ambulatory			Observational: 9				sensitivity to detect	Feasibility: Feasible for use in current and
blood pressure			Quasi-experimental: 5				optimal BP control defined	future practice
monitoring on			RCT: 5				by HBPM and ABP.	*
blood pressure							-	Level of Evidence: Systematic review-
control and			-Sample size range:				Correlation between	Level 1
patient			Observational: 210 to				HBPM and ABP is	
outcomes.			2.051				stronger than CBPM with	USPSTF: Grade: C: Level of certainty:
			Quasi-experimental: 53 to				ABP	Moderate
			121					
			RCT: 51 to 426					
			101.51 10 420					
			-Median follow up					
			Observational: 0 to 10.9					
			years					
			Quasi-experimental: 0 to					
			DCT: 0.5 to 12 mm also					
			RC1: 0.5 to 12 weeks					
			Standard and and					
			-Study Location:					
			United States: 3					
			Belgium: I					
			Japan: 3					
			Italy: 4					
			Spain: 2					
			Australia: 1					
			Brazil: 2					
			Switzerland: 1					
			Finland: 1					
			Germany: 1					
			Attrition: none					

Cairns.	None	Mixed	n = 68	IV1: HBPM vs	Semi-structured	Qualitative	• Control	Strengths: ↑ patient involvement, adequate
Tucker	stated	methods		CBPM	interviews	analysis	-IG: 1 control 1 responsibility	length of follow up \uparrow patient control in BP
Crawford	stated	study	Recruited from five	CD1 III	provided	unurjoio	-CG: variable responses	management single reviewer for
McManus		study	National Health	DV: natients'	reproducible		regarding control responsibility	qualitative analysis of interviews
Powell			Service hospital sites	nercentions	format for		and med adjustment	quantitative component
2020			in England during	perceptions	consistency		Convenience	quantitative component.
Implementin			nregnancy		consistency.		IC: variable responses on	Limitations: potential for bias because all
o self-			Interviews took place		Likert scale (1-5)		-IG. Variable responses on	who interviewed were enrolled in RCT
management			after delivery		was used for		with provider	lack of independent researchers (members
· A mixed			unter denivery.		natient responses		CC: variable responses on	of the trial team conducted interviews)
methods			Characteristics:		to standardized		access to care difficulty making	English language only for interview
study of			-Age		questions in both		access to care, difficulty making	English language only for interview
women's			[IG: 32.5 (+5.0), CG:		groups		with provider	Risk/harm: lack of BP control and
experiences			$[10.32.3(\pm 3.0), 00.$		groups.		Confidence Communication 8	development of complications
of a			$M_{000} \mathbf{PMI}$				• Confidence, Communication, &	development of complications
postpartum			-INICAL DIVIL. $[IC, 29, 9, (\pm 9, 1), CC,$				<u>Knowledge</u> IG: † confidence in	Feasibility: Feasible for use in current and
hypertension			$[10: 28.8 (\pm 0.1), C0:$				-IO. confidence in	future practice
intervention			$28.5 (\pm 9.0)$]				knowledge of BD readings was	Turne Provide
(SNAP-HT)			-rarity: 0, (IC: 22, CC: 22)				halpful	Level of Evidence: Mixed-Methods study-
().			0: (10: 22 CO: 22)				CC: variable responses	Level 5
			≥1: (IG: 12 CG: 12)				-CO. variable responses	200010
			-Median Gestation				providers and provider	USPSTF: Grade: C: Level of certainty:
			at Diagnosis:				knowledge	Moderate
			(IG: 36.1, CG: 34.9)				Concern	
			Attaition: Eailuna ta				IC: HRPM anviety	
			Aurition: Failure to					
			interview			Mean (SD)	IG only questions:	
			(IG: 2, CG: 8)			· · · ·	-Fit with condition: [4weeks:	
			(10.2, 00.0).				4 8(0 4) 6 months; 4 8 (0 5)]	
							-Fase/Difficulty of use: [4weeks	
							49(0.3) 6 months: $49(0.4)$]	
							-Change in lifestyle: [4weeks:	
							4 1(0.9) 6 months: 4 4 (0.9)]	
							-Likely to recommend: [4weeks:	
							4.9(0.3), 6 months; 4.9(0.4)]	
							-Likely to continue: [4weeks:	
							4.1(0.9), 6 months: $4.4(0.9)$]	
						Adjusted	4 weeks: 0.6 (95% CI 0.2 to 1.1)	
						Difference	6 weeks: 0.7(95% CI 0.3 to 1.2)	
						Between		
						Groups		

Aekplakorn	None	RCT	n = 2.24	IV1: HBPM vs	Automated BP	Mean	SBP at 6 months: (IG: 137.4	Strengths: 1 patient awareness and
Surivawongn	stated			CBPM	device (Omron		CG: 137.9)	compliance to medications, adequate
aisal	Stated		Recruited from a	CDIM	model HFM-		DBP at 6 months: (IG: 76.4 CG:	length of follow up, rules out WCH
Tansirisithik			community hospital	DV · BP control	7117)		76 0)	lengen of follow up, fulles out if offi
ul			registry for natients	D V. DI Control	, , .		SBP at 12 months: (IG: 136.4	Limitations: sample size_lack of
Sakulninat			living in Bang phli		Japanese Society		CG: 136.8)	blinding low percentage of complete BP
&			district Sautprakarn		of Hypertension		DBP at 12 months: (IG: 78.1	records details of meds at follow up not
Charoensuk.			providence		guideline 2003:		CG: 78.1)	provided.
2016.			F		BP measured			F
Effectivenes			Characteristics:		twice daily-			Risk/harm: lack of BP control and
s of self-			-Age:		morning and	Mean	6 months: (SBP: -2.9, DBP: -0.6)	development of complications
monitoring			[IG: 58(+9.4), CG:		evening (three	Difference	12 months: (SPB: -2.5, DBP-1.2)	1 1
blood			60.83(+9.0)]		readings obtained			Feasibility: Feasible for use in current and
pressure in			-Sex (M):		each time).			future practice
primary care:			[IG: 39, CG: 39]		,	Percentages	Uncontrolled BP:	1
A			-BMI:		Each patient was	(%)	All:	Level of Evidence: RCT- Level 2
randomized			[IG: 27.3 (+5.2), CG:		instructed		-Baseline (IG: 97, CG: 88)	
controlled			264(+45)]		individually		-6 Months (IG: 41, CG: 43)	USPSTF: Grade: B; Level of certainty:
trial.			-Smokers:		about how to use		-12 Months (IG: 51, CG: 52)	Moderate
			[IG: 5.4%, CG:		the monitor,		<u><60:</u>	
			12.4%]		record, and		-Baseline (IG: 47, CG: 34)	
			-# of BP meds:		interpret the BP		-6 Months (IG: 17, CG: 15)	
			1: (IG: 32, CG: 39)		data.		-12 Months (IG: 30, CG: 18)	
			2: (IG: 51, CG: 52)				<u>≥60:</u>	
			\geq 3: (IG: 28, CG: 22)		Uncontrolled BP		-Baseline (IG: 50, CG: 54)	
			-SBP:		was defined by		-6 Months (IG: 24, CG: 28)	
			[IG: 149.4 (±11.4),		$SBP \ge 140 \text{ mm}$		-12 Months (IG: 21, CG: 36)	
			CG: 147.2 (±14.9)]		Hg or DBP \geq 90.			
			-DBP:					
			[IG: 83.4 (+9.9), CG:			Difference	<u>All</u> :	
			82.2 (+11.7)]			Between	Baseline to 6 Months: 0.13	
			0212 (2111/)]			Groups (p	Baseline to 12 Months: 0.13	
			Attrition: At six			value)	$\frac{\leq 60:}{2}$	
			months, one patient				Baseline to 6 Months: 0.28	
			from the IG and one				Baseline to 12 Months: 0.78	
			patient from the CG				≥ 00 : Descline to 6 Monther 0.24	
			withdrew.				Daseline to 0 Months: 0.24	
							baseline to 12 months. 0.02	

r		1	1	r	T		1	r
Spirk, Noll,	None	Cohort	n = 1, 268	IV1: HBPM vs	Automated BP	Percentages	BP Goal Attainment after 3	Strengths: large sample size, ↑ patient
Burnier,	stated	study		CBPM	device (Microlife	(%)	months:	awareness,
Rimoldi, Noll,			30 to 36 physicians		3AC1-1PC,		- HBPM: 64%	intervention, cost-effective, automated BP
& Sudano,			from each of the 10	DV: patients'	Average Mode)		- CBPM only: 57%	device with storage.
2018, Effect			sectors in	awareness, BP				-
of home blood			Switzerland were	control	BP levels were		Patient awareness of BP goals:	Limitations: observational, short follow up
pressure			randomly chosen		automatically		- HBPM: 81%	period, lack of blinding and randomization,
monitoring on			from a registry to		stored on the		-CBPM only: 70%	no exclusion criteria, medication therapy
patient's			enroll up to 5 patients		device for			used alongside HBPM.
awareness and			in the study.		physician review.	Mean (SD)	<u>SBP</u> :	
goal							- HBMP: 138 ± 13	Risk/harm: lack of BP control and
attainment			Characteristics:		Detailed training		- CBPM only: 139 ± 14	development of complications
under			-Age: 61.2 ± 12.5		sessions were		2	
antihypertensi			-Sex (F): 48.6%		provided on		DBP:	Feasibility: Feasible for use in current and
ve therapy:			-BMI: 28.4 +5.0		HBPM and		- HBMP· 83 + 9	future practice
The factors			-Diabetes: 18.8%		documentation.		- CBPM only: 84 ± 9	•
influencing			-SBP: 161 5 + 17 1				$CDI W Olly: 04 \pm 9$	Level of Evidence: Cohort study- Level 4
results in anti-			DRP: 05.7 ± 10.8		HBPM was		Peduction in SBP between	
hypertensive			HDDM : 50.99/		performed once		groups:	USPSTF: Grade: B: Level of certainty:
treatment			- IIBI WI. 59.878		weekly and on		Total: 22.8	Moderate
(FIRST)			Attrition, 117 did not		the 6 consecutive		- Iotal. 23.6	
study.			Authon. 11/ did not		days prior to each		- Indesartan 500mg + $\Pi C T \Sigma$	
studyt			show up for follow		physician visit.		12.5mg: 20.4	
			up appointment at 3		phijotetan viola		D 1 C DDD1	
			months		BP taken after		Reduction in DBP between	
					resting for 5		groups:	
					minutes hefere		- Total: 13.2	
					dministration in a		- Irbesartan 300mg + HCTZ	
					drug intake, in a		12.5mg: 13.3	
					quiet room,			
					seated, and after			
					> 30 minutes			
					without smoking,			
					catfeine, meal, or			
					exercise.			

Legend: RCT: randomized controlled trial, SOG: self-observation group, CG: control group, IG: intervention group, DM: diabetes mellitus, CHOL: serum cholesterol, IV: independent variable, HBPM: home blood pressure monitoring, CBPM: clinic blood pressure monitoring, DV: dependent variable, BP: blood pressure, CBP: clinic blood pressure, SBP: systolic blood pressure, DBP: diastolic BP, HBP: home blood pressure, ABP: ambulatory blood pressure, TOD: target organ disease, AS: aortic stiffness, LVRWT: left ventricular relative wall thickness, LVMI: left ventricular mass index, LVEF: left ventricular ejection fraction, LAA: left atrial area, LVFP: left ventricular filling pressure, WB: White British, HOME BP: Home and online management and evaluation of hypertension, HTN: hypertension, CoCo: Color-coded, GPs: general practitioners, AM: morning, F/U: follow-up, HTN: hypertension, CV: cardiovascular, DEM: dementia, MCI: mild cognitive impairment, CN: cognitively normal, WCH: white coat hypertension



Appendix B

Appendix C: Instrument

Home Blood Pressure Log Use this logbook to document your blood pressure readings



	Systolic	Diastolic	Comments
Day 1			
Day 2			
Day 3			
Day 4			
Day 5			
Day 6			
Day 7			